Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLIM LIVER: Semaglutide for NAFLD in HIV
NCT04216589Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2021
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of semaglutide in non-alcoholic fatty liver disease (NAFLD), sponsored by National Institute of Allergy and Infectious Diseases. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04216589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216589.